Active — Not RecruitingPhase 4

HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

Finland126 participantsStarted 2016-05

Plain-language summary

Pancreatic resections carry a high risk for complications, especially pancreatic fistula. Both hydrocortisone and pasireotide have been shown to be effective in reducing complications in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these two drugs in preventing complications of pancreatic surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients scheduled for pancreatic surgery (pancreaticoduodenectomy, distal pancreatectomy, enucleation, or other type of pancreatic resection) Exclusion Criteria: * Preoperative exclusion criteria: * Atrophic pancreas and/or dilated pancreatic duct at the site of planned pancreatic transsection (applies only to patients undergoing pancreaticoduodenectomy) * Total pancreatectomy planned * Allergy or other contraindication for hydrocortisone or pasireotide * Age \< 18 years * No informed consent * Intraoperative exclusion criteria: * Pancreatic resection cancelled (e.g. disseminated cancer) * Hard pancreas and/or dilated pancreatic duct discovered during operation (applies only to patients undergoing pancreaticoduodenectomy) * Total pancreatectomy is performed

What they're measuring

Comprehensive Complication Index

Timeframe: 30 days postoperatively

Trial details

NCT IDNCT02775227

SponsorHelsinki University Central Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01

View on ClinicalTrials.gov More Pancreatic Fistula trials